CLINICAL TRIALS PROFILE FOR ORAPRED ODT
✉ Email this page to a colleague
All Clinical Trials for Orapred Odt
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00079105 ↗ | A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years | Completed | Newcastle-upon-Tyne Hospitals NHS Trust | Phase 2 | 2004-01-01 | RATIONALE: Drugs used in chemotherapy, such as vinblastine, cyclophosphamide, procarbazine, prednisolone, etoposide, mitoxantrone, and bleomycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating older patients with previously untreated Hodgkin's lymphoma. |
| NCT00798616 ↗ | Steroids Helping Albuterol Responders Exclusively | Withdrawn | University Hospitals Cleveland Medical Center | N/A | 1969-12-31 | The purpose of the study is to determine whether corticosteroids are beneficial to children with bronchiolitis whose breathing gets better after being given a breathing treatment with albuterol. |
| NCT01211665 ↗ | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | Terminated | Elan Pharmaceuticals | Phase 4 | 2010-09-01 | The objectives of this study are to explore the effects of administering high-dose corticosteroids to participants who developed progressive multifocal leukoencephalopathy (PML) while on natalizumab as measured by time-course change in functional status based on Karnofsky Performance Status Index through 6 months following the completion of plasma exchange (PLEX; or equivalent), survival at 6 months following the completion of PLEX (or equivalent), and incidence and severity of adverse events (AEs) and serious adverse events (SAEs); to characterize the evolution of immune reconstitution inflammatory syndrome (IRIS) as measured by time course changes in Global Clinical Impression of Improvement (GCI-I), Symbol Digit Modalities Test (SDMT), brain magnetic resonance imaging (MRI), magnetoencephalography (MEG), chemokines, cytokines, C-reactive protein (CRP), John Cunningham virus (JCV) load and cell count in cerebrospinal fluid (CSF); and to characterize the time course elimination of serum natalizumab concentrations in the study population following the last PLEX (or equivalent) procedure. |
| NCT01211665 ↗ | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | Terminated | Biogen | Phase 4 | 2010-09-01 | The objectives of this study are to explore the effects of administering high-dose corticosteroids to participants who developed progressive multifocal leukoencephalopathy (PML) while on natalizumab as measured by time-course change in functional status based on Karnofsky Performance Status Index through 6 months following the completion of plasma exchange (PLEX; or equivalent), survival at 6 months following the completion of PLEX (or equivalent), and incidence and severity of adverse events (AEs) and serious adverse events (SAEs); to characterize the evolution of immune reconstitution inflammatory syndrome (IRIS) as measured by time course changes in Global Clinical Impression of Improvement (GCI-I), Symbol Digit Modalities Test (SDMT), brain magnetic resonance imaging (MRI), magnetoencephalography (MEG), chemokines, cytokines, C-reactive protein (CRP), John Cunningham virus (JCV) load and cell count in cerebrospinal fluid (CSF); and to characterize the time course elimination of serum natalizumab concentrations in the study population following the last PLEX (or equivalent) procedure. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Orapred Odt
Condition Name
Clinical Trial Locations for Orapred Odt
Trials by Country
Clinical Trial Progress for Orapred Odt
Clinical Trial Phase
Clinical Trial Sponsors for Orapred Odt
Sponsor Name
